Clinical trial NCT04371445: Dextenza in the Post-op Management of Vitreoretinal Surgeries
Official title: Intracanalicular Dexamethasone Insert for Management of Post-operative Pain and Inflammation in Patients Undergoing Vitreoretinal Surgery
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Vitreoretinal Surgery
Ocular Inflammation
Post-operative Pain
Post-Operative Inflammation
Keywords: dexamethasone insert
Ocular Inflammation
Post-Operative Inflammation
Post-operative Pain
Lead sponsor: The Cleveland Clinic
Sponsor class: OTHER
Collaborators: name: Ocular Therapeutix, Inc.
First posted: 2020-05-01
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study will assess the control of inflammation at days 1, 7, 14, and 21 days following the vitreoretinal surgical procedure analyzing two randomized study arms: Intracanalicular dexamethasone insert group or topical steroid drop group.

Patients must be 18 years of age and older, of any race and either sex, requiring surgery with the procedure type of pars plana vitrectomy for either the indication of macular hole, epiretinal membrane removal, or vitreomacular traction.

Detailed description: Topical steroids are the current standard of care for managing postoperative pain and inflammation following vitreoretinal surgery. However, topical treatments are limited by the potential for patient non-adherence and variation in drug concentrations due to the intermittent nature of application. A corticosteroid insert, placed following surgery, provides the advantages of reliable and continuous drug delivery without the need for patients to adhere to a treatment regimen. Recently, DEXTENZA®, a dexamethasone intracanalicular insert was FDA-approved for the treatment of inflammation and pain following ophthalmic surgery. DEXTENZA® is placed into the canaliculus via the lower punctum and is designed to release steroid medication for 30 days.

The data is limited regarding the safety and efficacy of DEXTENZA® for postoperative management of vitreoretinal surgery. Herein, the aim of this study is to assess the management of pain and inflammation following retinal surgery when using a dexamethasone implant compared with topical steroids.

Eligibility criteria: Inclusion Criteria:

* Men and women \>18 years old
* Planning to undergo vitreoretinal surgery with the procedure type of pars plana vitrectomy for either the indication of macular hole, epiretinal membrane removal, or vitreomacular traction.

Exclusion Criteria:

* Patients undergoing combined cataract or glaucoma procedure, intraocular lens exchange, scleral buckle, and/or implant of a drug delivery system
* History of complications, trauma, adverse events, disease in nasolacrimal region, including dacryocystitis, canaliculitis in either eye
* Structural lid abnormalities such as ectropion or entropion in surgical eye
* Ongoing use of systemic narcotic pain relievers
* Presence of any intraocular inflammation (cells and flare) in the study eye at screening/baseline
* Pain score greater than "0" on the ocular pain assessment in the study eye at screening/baseline
* Active or chronic or recurrent uncontrolled ocular or systemic inflammatory disease, including diabetes
* Other ocular surgeries or procedures during the study period and/or 6 months prior
* Intraoperative complications
* Patients with history of glaucoma (defined as glaucoma requiring 2 or more drops, IOP at baseline greater than 25, or advanced optic nerve cupping). Patients with glaucoma or ocular hypertension controlled with a single drop can be enrolled.
* Patients with a known hypersensitivity to NSAIDs or steroids or any component of the study medication.
* Have used ocular, topical, or systemic NSAIDs within 7 days prior to procedure and during surgery.
* Use of intracameral or subconjunctival NSAIDs or steroids intraoperatively.
* Have used topical, ocular, inhaled or systemic steroids within 14 days prior to procedure
* Are pregnant or nursing/lactating
* Participation as a subject in any clinical study within the 30 days prior to randomization.
* Surgeries using 20 gauge or 23 gauge instruments.

Primary outcomes:
measure: To assess control of inflammation following the vitreoretinal surgical procedure.
timeFrame: day 14 following surgery
Secondary outcomes:
measure: The patient reporting of pain following surgery using visual analog pain scale at days 1, 3, 7, 14, and 21 following surgery.
timeFrame: days 1, 3, 7, 14, and 21 following surgery
measure: Inflammation assessed on Anterior Segment OCT by masked grading at days 1, 7, 14, and 21 following surgery.
timeFrame: days 1, 7, 14, and 21 following surgery
measure: Mean change in Best Corrected Visual Acuity (BCVA) from baseline to day 21 following surgery.
timeFrame: day 21 following surgery
measure: % of patients with rebound inflammation defined as a two-step worsening of inflammation by SUN grading.
timeFrame: day 21 following surgery
measure: % of patients receiving rescue treatment.
timeFrame: days 1, 7, 14, and 21 following surgery
measure: % of patients with postoperative management via telephone or electronic messaging
timeFrame: day 21 following surgery
measure: The incidence and severity of ocular and non-ocular adverse events (AEs) and serious AEs between arms.
timeFrame: day 21 following surgery
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Cole Eye Institute, Cleveland Clinic
state: Ohio
Study officials:
affiliation: Cole Eye Institute, Cleveland Clinic
name: Katherine Talcott, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hermann MM, Ustundag C, Diestelhorst M. Electronic compliance monitoring of topical treatment after ophthalmic surgery. Int Ophthalmol. 2010 Aug;30(4):385-90. doi: 10.1007/s10792-010-9362-3. Epub 2010 Apr 7.
citation: An JA, Kasner O, Samek DA, Levesque V. Evaluation of eyedrop administration by inexperienced patients after cataract surgery. J Cataract Refract Surg. 2014 Nov;40(11):1857-61. doi: 10.1016/j.jcrs.2014.02.037. Epub 2014 Sep 22.
citation: Tyson SL, Bafna S, Gira JP, Goldberg DF, Jones JJ, Jones MP, Kim JK, Martel JM, Nordlund ML, Piovanetti-Perez IK, Singh IP, Metzinger JL, Mulani D, Sane S, Talamo JH, Goldstein MH; Dextenza Study Group. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2019 Feb;45(2):204-212. doi: 10.1016/j.jcrs.2018.09.023. Epub 2018 Oct 24.
citation: Gira JP, Sampson R, Silverstein SM, Walters TR, Metzinger JL, Talamo JH. Evaluating the patient experience after implantation of a 0.4 mg sustained release dexamethasone intracanalicular insert (Dextenza): results of a qualitative survey. Patient Prefer Adherence. 2017 Mar 8;11:487-494. doi: 10.2147/PPA.S126283. eCollection 2017.
citation: Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509-16. doi: 10.1016/j.ajo.2005.03.057.